Evidence map›Paper›PMID 38935260›Full record

ReviewMolecular biotechnology2025

Clearing the Path: Exploring Apoptotic Cell Clearance in Inflammatory and Autoimmune Disorders for Therapeutic Advancements.

Shadi Ghorbanzadeh, Javad Yaghmoorian Khojini, Reza Abouali, Sajad Alimardan, Mohammad Zahedi, Zahra Tahershamsi, Amir Tajbakhsh, Seyed Mohammad Gheibihayat

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shadi Ghorbanzadeh *Department of Medical Genetics, Faculty of Medicine, Hormozgan University of Medical Science, Bandar Abbas, Iran.
Javad Yaghmoorian Khojini *Department of Medical Biotechnology, School of Medicine, Shahid Sadoughi University of Medical Sciences, P.O. Box: 8915173143, Yazd, IR, Iran.
Reza AboualiDepartment of Health Sciences, Interdisciplinary Research Center of Autoimmune Diseases-IRCAD, Università del Piemonte Orientale, Novara, Italy.
Sajad AlimardanDepartment of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.
Mohammad ZahediDepartment of Medical Biotechnology, School of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran.
Zahra TahershamsiDepartment of Biophysics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
Amir TajbakhshPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Seyed Mohammad GheibihayatDepartment of Medical Biotechnology, School of Medicine, Shahid Sadoughi University of Medical Sciences, P.O. Box: 8915173143, Yazd, IR, Iran. gheibi65@yahoo.com.ORCID http://orcid.org/0000-0002-1378-118X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory and autoimmune disorders, characterized by dysregulated immune responses leading to tissue damage and chronic inflammation, present significant health challenges. This review uniquely focuses on efferocytosis-the phagocyte-mediated clearance of apoptotic cells-and its pivotal role in these disorders. We delve into the intricate mechanisms of efferocytosis' four stages and their implications in disease pathogenesis, distinguishing our study from previous literature. Our findings highlight impaired efferocytosis in conditions like atherosclerosis and asthma, proposing its targeting as a novel therapeutic strategy. We discuss the therapeutic potential of efferocytosis in modulating immune responses and resolving inflammation, offering a new perspective in treating inflammatory disorders.

Indexed as

ApoptosisAutoimmune DiseasesInflammationPhagocytosisAnimalsEfferocytosisHumansPhagocytesAnti-inflammatory cytokinesApoptotic cell clearanceChronic inflammatory diseasePhagocytesResolution of inflammationTargeted therapy

Identifiers

PMID38935260

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.